tbuckley/cabot-search huggingface dataset:
Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction
Authors: Hidenori Tani, Taketaro Sadahiro, Yu Yamada, Mari Isomi, Hiroyuki Yamakawa, Ryo Fujita, Yuto Abe, Tatsuya Akiyama, Koji Nakano, Yuta Kuze, Masahide Seki, Yutaka Suzuki, Manabu Fujisawa, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Keiichi Fukuda, Masaki Ieda
Journal: Circulation (2022)

Because adult cardiomyocytes have little regenerative capacity, resident cardiac fibroblasts (CFs) synthesize extracellular matrix after myocardial infarction (MI) to form fibrosis, leading to cardiac dysfunction and heart failure. Therapies that can regenerate the myocardium and reverse fibrosis in chronic MI are lacking. The overexpression of cardiac transcription factors, including Mef2c/Gata4/Tbx5/Hand2 (MGTH), can directly reprogram CFs into induced cardiomyocytes (iCMs) and improve cardiac function under acute MI. However, the ability of in vivo cardiac reprogramming to repair chronic MI with established scars is undetermined.We generated a novel Tcf21iCre/reporter/MGTH2A transgenic mouse system in which tamoxifen treatment could induce both MGTH and reporter expression in the resident CFs for cardiac reprogramming and fibroblast lineage tracing. We first tested the efficacy of this transgenic system in vitro and in vivo for acute MI. Next, we analyzed in vivo cardiac reprogramming and fusion events under chronic MI using Tcf21iCre/Tomato/MGTH2A and Tcf21iCre/mTmG/MGTH2A mice, respectively. Microarray and single-cell RNA sequencing were performed to determine the mechanism of cardiac repair by in vivo reprogramming.We confirmed the efficacy of transgenic in vitro and in vivo cardiac reprogramming for acute MI. In chronic MI, in vivo cardiac reprogramming converted ≈2% of resident CFs into iCMs, in which a majority of iCMs were generated by means of bona fide cardiac reprogramming rather than by fusion with cardiomyocytes. Cardiac reprogramming significantly improved myocardial contraction and reduced fibrosis in chronic MI. Microarray analyses revealed that the overexpression of MGTH activated cardiac program and concomitantly suppressed fibroblast and inflammatory signatures in chronic MI. Single-cell RNA sequencing demonstrated that resident CFs consisted of 7 subclusters, in which the profibrotic CF population increased under chronic MI. Cardiac reprogramming suppressed fibroblastic gene expression in chronic MI by means of conversion of profibrotic CFs to a quiescent antifibrotic state. MGTH overexpression induced antifibrotic effects partly by suppression of Meox1, a central regulator of fibroblast activation.These results demonstrate that cardiac reprogramming could repair chronic MI by means of myocardial regeneration and reduction of fibrosis. These findings present opportunities for the development of new therapies for chronic MI and heart failure.
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients
Authors: Giorgia Massacci, Veronica Venafra, Sara Latini, Valeria Bica, Giusj Monia Pugliese, Simone Graziosi, Felix Klingelhuber, Natalie Krahmer, Thomas Fischer, Dimitrios Mougiakakos, Martin Boettcher, Livia Perfetto, Francesca Sacco
Journal: Leukemia (2022)

Abstract The insertion site of the internal tandem duplications (ITDs) in the FLT3 gene affects the sensitivity to tyrosine kinase inhibitors (TKIs) therapy in acute myeloid leukemia (AML). Patients with the ITD in the tyrosine kinase domain lack effective therapeutic options. Here, to identify genotype-driven strategies increasing the TKI therapy efficacy, we developed SignalingProfiler , a strategy supporting the integration of high-sensitive mass spectrometry-based (phospho)proteomics, RNA sequencing datasets with literature-derived signaling networks. The approach generated FLT3-ITD genotype-specific predictive models and revealed a conserved role of the WEE1-CDK1 axis in TKIs resistance. Remarkably, pharmacological inhibition of the WEE1 kinase synergizes and strengthens the pro-apoptotic effect of TKIs therapy in cell lines and patient-derived primary blasts. Finally, we propose a new molecular mechanism of TKIs resistance in AML and suggest the combination of WEE1 inhibitor and TKI as a therapeutic option to improve patients clinical outcome.
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms
Authors: Carla S. Walti, Anna B. Halpern, Hu Xie, Erika S. Kiem, E. Lisa Chung, Kelda G. Schonhoff, Emily M. Huebner, Colleen Delaney, Catherine Liu, Steven A. Pergam, Guang-Shing Cheng, Louise E. Kimball, Wendy M. Leisenring, Michael Boeckh, Roland B. Walter, Joshua A. Hill
Journal: Leukemia (2022)
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009
Authors: Thomas Lehrnbecher, Andreas H. Groll, Simone Cesaro, Julia Alten, Andishe Attarbaschi, Draga Barbaric, Nicole Bodmer, Valentino Conter, Shai Izraeli, Georg Mann, Anja Möricke, Felix Niggli, Martin Schrappe, Jan Stary, Ester Zapotocka, Martin Zimmermann, Sarah Elitzur
Journal: Leukemia (2022)

Abstract In children with acute lymphoblastic leukemia (ALL), risk groups for invasive fungal disease (IFD) with need for antifungal prophylaxis are not well characterized, and with the advent of new antifungal compounds, current data on outcome are scarce. Prospectively captured serious adverse event reports of children enrolled in the international, multi-center clinical trial AIEOP-BFM ALL2009 were screened for proven/probable IFD, defined according to the updated EORTC/MSG consensus definitions. In a total of 6136 children (median age 5.2 years), 224 proven/probable IFDs (65 yeast and 159 mold) were reported. By logistic regression, the risk for proven/probable IFDs was significantly increased in children ≥12 years and those with a blast count ≥10% in the bone marrow on day 15 ( P &lt; 0.0001 each). Proven/probable IFDs had a 6-week and 12-week mortality of 10.7% and 11.2%, respectively. In the multivariate analysis, the hazard ratio for event-free and overall survival was significantly increased for proven/probable IFD, age ≥12 years, and insufficient response to therapy ( P &lt; 0.001, each). Our data define older children with ALL and those with insufficient treatment-response at high risk for IFD. As we show that IFD is an independent risk factor for event-free and overall survival, these patients may benefit from targeted antifungal prophylaxis.
Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma
Authors: Marta Sureda-Gómez, Patricia Balsas, Marta-Leonor Rodríguez, Ferran Nadeu, Anna De Bolòs, Álvaro Eguileor, Marta Kulis, Giancarlo Castellano, Cristina López, Eva Giné, Santiago Demajo, Pedro Jares, José I. Martín-Subero, Silvia Beà, Elias Campo, Virginia Amador
Journal: Leukemia (2022)

Abstract SOX11 overexpression has been associated with aggressive behavior of mantle cell lymphomas (MCL). SOX11 is overexpressed in embryonic and cancer stem cells (CSC) of some tumors. Although CSC have been isolated from primary MCL, their relationship to SOX11 expression and contribution to MCL pathogenesis and clinical evolution remain unknown. Here, we observed enrichment in leukemic and hematopoietic stem cells gene signatures in SOX11+ compared to SOX11– MCL primary cases. Musashi-2 (MSI2) emerged as one of the most significant upregulated stem cell-related genes in SOX11+ MCLs. SOX11 is directly bound to the MSI2 promoter upregulating its expression in vitro. MSI2 intronic enhancers were strongly activated in SOX11+ MCL cell lines and primary cases. MSI2 upregulation was significantly associated with poor overall survival independently of other high-risk features of MCL. MSI2 knockdown decreased the expression of genes related to apoptosis and stem cell features and significantly reduced clonogenic growth, tumor cell survival and chemoresistance in MCL cells. MSI2-knockdown cells had reduced tumorigenic engraftment into mice bone marrow and spleen compared to control cells in xenotransplanted mouse models. Our results suggest that MSI2 might play a key role in sustaining stemness and tumor cell survival, representing a possible novel target for therapeutic interventions in MCL.
15. Management of Diabetes in Pregnancy:<i>Standards of Care in Diabetes—2023</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2022)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
12. Retinopathy, Neuropathy, and Foot Care:<i>Standards of Care in Diabetes—2023</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Christopher H. Gibbons, John M. Giurini, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton, Jennifer K. Sun, Robert A. Gabbay
Journal: Diabetes Care (2022)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
6. Glycemic Targets: <i>Standards of Care in Diabetes—2023</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2022)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells
Authors: Ettaib El Marabti, Omar Abdel-Wahab
Journal: Clinical Cancer Research (2022)

Summary Chimeric antigen receptor T (CAR-T) cells directed against CD19 have transformed the therapy of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). A recent study reports promising activity and safety of CD19 CAR-T cells generated from naïve, stem, and central memory T cells in adults with R/R B-ALL. See related article by Aldoss et al., p. 742
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Authors: Regis Peffault de Latour, Alexander Roeth, Austin Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M de Castro, Eros Di Bona, Hubert Schrezenmeier, Saskia MC Langemeijer, Wilma Barcellini, Suzanne Tavitian, Jens Panse, Philippe Schafhausen, Vitor AQ Mauad, Cecile Kerloeguen, Rafael Levitch, Rakesh Kumar, Christine Thorburn, Samopriyo Maitra, Marion Dahlke, Antonio M Risitano
Journal: Blood (2022)
Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Authors: Mark R. Litzow, Zhuoxin Sun, Elisabeth Paietta, Ryan J. Mattison, Hillard M Lazarus, Jacob M. Rowe, Daniel A. Arber, Charles G. Mullighan, Cheryl L Willman, Yanming Zhang, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Keith W. Pratz, Shira Dinner, Noelle V. Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Richard F. Little, Selina M. Luger, Martin S. Tallman
Journal: Blood (2022)
Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
Authors: Gerald Illerhaus, Andrés J.M. Ferreri, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer, Alexander Roeth, Thomas Weber, Gerlinde Egerer, Thomas Ernst, Bernd Hertenstein, Georg Lenz, Guido Kobbe, Uta Brunnberg, Christian Schmidt, Michael Kneba, Martin Dreyling, Robert Möhle, Jens Panse, Thomas Heinicke, Sebastian Schroll, Thomas S. Larsen, Hans Salwender, Ralph Naumann, Georg Hess, Lorenz Thurner, Tobias Pukrop, Ulrich Keller, Anne Kirsti Blystadt, Frank P. Kroschinsky, Francesca Re, Elisa Pulczynski, Lorella Orsucci, Lisa Pospiech, Martina Deckert, Maurilio Ponzoni, Julia Wendler, Elke Valk, Teresa Calimeri, Benjamin Kasenda, Martin Trepel, Heidi Fricker, Philipp von Gottberg, Elvira Burger, Gabriele Ihorst, Olga Grishina, Claudia Hader, Emanuele Zucca, Jürgen Finke, Elisabeth Schorb
Journal: Blood (2022)
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Authors: Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Megan (Der Yu) Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Journal: Blood (2022)
Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial
Authors: Siobhan Quenby, Katie Booth, Louise Hiller, Arri Coomarasamy, Eva Hamulyák, Luuk Scheres, Paulien G. de Jong, Thijs van Haaps, Lauren J. Ewington, Shreeya Tewary, Mariëtte Goddijn, Saskia Middeldorp
Journal: Blood (2022)
Prrx1 marks stem cells for bone, white adipose tissue and dermis in adult mice
Authors: Huijuan Liu, Ping Li, Shaoyang Zhang, Jinnan Xiang, Ruichen Yang, Jiajia Liu, Md Shafiquzzaman, Soma Biswas, Zhanying Wei, Zhenlin Zhang, Xin Zhou, Feng Yin, Yangli Xie, Stephen P. Goff, Lin Chen, Baojie Li
Journal: Nature Genetics (2022)
Genomic characterization and therapeutic utilization of IL-13-responsive sequences in asthma
Authors: Kyung Duk Koh, Luke R. Bonser, Walter L. Eckalbar, Ofer Yizhar-Barnea, Jiangshan Shen, Xiaoning Zeng, Kirsten L. Hargett, Dingyuan I. Sun, Lorna T. Zlock, Walter E. Finkbeiner, Nadav Ahituv, David J. Erle
Journal: Cell Genomics (2022)

Epithelial responses to the cytokine interleukin-13 (IL-13) cause airway obstruction in asthma. Here we utilized multiple genomic techniques to identify IL-13-responsive regulatory elements in bronchial epithelial cells and used these data to develop a CRISPR interference (CRISPRi)-based therapeutic approach to downregulate airway obstruction-inducing genes in a cell type- and IL-13-specific manner. Using single-cell RNA sequencing (scRNA-seq) and acetylated lysine 27 on histone 3 (H3K27ac) chromatin immunoprecipitation sequencing (ChIP-seq) in primary human bronchial epithelial cells, we identified IL-13-responsive genes and regulatory elements. These sequences were functionally validated and optimized via massively parallel reporter assays (MPRAs) for IL-13-inducible activity. The top secretory cell-selective sequence from the MPRA, a novel, distal enhancer of the sterile alpha motif pointed domain containing E-26 transformation-specific transcription factor (SPDEF) gene, was utilized to drive CRISPRi and knock down SPDEF or mucin 5AC (MUC5AC), both involved in pathologic mucus production in asthma. Our work provides a catalog of cell type-specific genes and regulatory elements involved in IL-13 bronchial epithelial response and showcases their use for therapeutic purposes.
Hepatic fat as a novel marker for high-risk coronary atherosclerotic plaque features in familial hypercholesterolaemia
Authors: Gavin Huangfu, Biyanka Jaltotage, Jing Pang, Nick S R Lan, Arun Abraham, Jacobus Otto, Abdul R Ihdayhid, James M Rankin, Benjamin J W Chow, Gerald F Watts, Oyekoya T Ayonrinde, Girish Dwivedi
Journal: Metabolism (2022)
Associations between objectively measured sleep parameters and cognition in healthy older adults: A meta-analysis
Authors: Shuo Qin, Ruth L.F. Leong, Ju Lynn Ong, Michael W.L. Chee
Journal: Sleep Medicine Reviews (2022)

Multiple studies have examined associations between sleep and cognition in older adults, but a majority of these depend on self-reports on sleep and utilize cognitive tests that assess overall cognitive function. The current meta-analysis involved 72 independent studies and sought to quantify associations between objectively measured sleep parameters and cognitive performance in healthy older adults. Both sleep macrostructure (e.g., sleep duration, continuity, and stages) and microstructure (e.g., slow wave activity and spindle activity) were evaluated. For macrostructure, lower restlessness at night was associated with better memory performance (r = 0.43, p = 0.02), while lower sleep onset latency was associated with better executive functioning (r = 0.28, p = 0.03). Greater relative amount of N2 and REM sleep, but not N3, positively correlated with cognitive performance. The association between microstructure and cognition in older adults was marginally significant. This relationship was moderated by age (z = 0.07, p < 0.01), education (z = 0.26, p = 0.03), and percentage of female participants (z = 0.01, p < 0.01). The current meta-analysis emphasizes the importance of considering objective sleep measures to understand the relationship between sleep and cognition in healthy older adults. These results also form a base from which researchers using wearable sleep technology and measuring behavior through computerized testing tools can evaluate their findings.
Enhancement of T cell infiltration via tumor-targeted Th9 cell delivery improves the efficacy of antitumor immunotherapy of solid tumors
Authors: Tao Chen, Yucheng Xue, Shengdong Wang, Jinwei Lu, Hao Zhou, Wenkan Zhang, Zhiyi Zhou, Binghao Li, Yong Li, Zenan Wang, Changwei Li, Yinwang Eloy, Hangxiang Sun, Yihang Shen, Mohamed Diaty Diarra, Chang Ge, Xupeng Chai, Haochen Mou, Peng Lin, Xiaohua Yu, Zhaoming Ye
Journal: Bioactive Materials (2022)

Insufficient infiltration of T cells severely compromises the antitumor efficacy of adoptive cell therapy (ACT) against solid tumors. Here, we present a facile immune cell surface engineering strategy aiming to substantially enhance the anti-tumor efficacy of Th9-mediated ACT by rapidly identifying tumor-specific binding ligands and improving the infiltration of infused cells into solid tumors. Non-genetic decoration of Th9 cells with tumor-targeting peptide screened from phage display not only allowed precise targeted ACT against highly heterogeneous solid tumors but also substantially enhanced infiltration of CD8+ T cells, which led to improved antitumor outcomes. Mechanistically, infusion of Th9 cells modified with tumor-specific binding ligands facilitated the enhanced distribution of tumor-killing cells and remodeled the immunosuppressive microenvironment of solid tumors via IL-9 mediated immunomodulation. Overall, we presented a simple, cost-effective, and cell-friendly strategy to enhance the efficacy of ACT against solid tumors with the potential to complement the current ACT.
Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)—A Randomized Controlled Trial
Authors: Anna Obermayer, Norbert J. Tripolt, Peter N. Pferschy, Harald Kojzar, Faisal Aziz, Alexander Müller, Markus Schauer, Abderrahim Oulhaj, Felix Aberer, Caren Sourij, Hansjörg Habisch, Tobias Madl, Thomas Pieber, Barbara Obermayer-Pietsch, Vanessa Stadlbauer, Harald Sourij
Journal: Diabetes Care (2022)

OBJECTIVE To investigate the safety and feasibility of 3 nonconsecutive days of intermittent fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS Forty-six people were randomized to an IF or control group. Dietary counseling and continuous glucose monitoring was provided. Coprimary end points were the change in HbA1c from baseline to 12 weeks and a composite end point (weight reduction ≥2%, insulin dose reduction ≥10%, and HbA1c reduction ≥3 mmol/mol). RESULTS The IF group showed a significant HbA1c reduction (−7.3 ± 12.0 mmol/mol) compared with the control group (0.1 ± 6.1 mmol/mol) over 12 weeks (P = 0.012). The coprimary end point was achieved by 8 people in the IF and none in the control group (P &amp;lt; 0.001). No severe hypoglycemia occurred. CONCLUSIONS IF is a safe and feasible dietary option to ameliorate glycemic control while reducing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.